Abstract
The physiological role(s) of mammalian plasma lipoproteins is to transport hydrophobic molecules (primarily cholesterol and triacylglycerols) to their respective destinations. Lipoproteins have also been studied as drug-delivery agents due to their advantageous payload capacity, long residence time in the circulation and biocompatibility. The purpose of this review is to briefly discuss current findings with the focus on each type of formulation's potential for clinical applications. Regarding utilizing lipoprotein type formulation for cancer therapeutics, their potential for tumor-selective delivery is also discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 257-268 |
| Number of pages | 12 |
| Journal | Therapeutic Delivery |
| Volume | 9 |
| Issue number | 4 |
| DOIs | |
| State | Published - 1 Jan 2018 |
Keywords
- HDL
- LDL
- cancer therapy
- discoidal nanoparticles
- drug delivery
- lipoproteins
- rHDL
Fingerprint Dive into the research topics of 'Lipoproteins for therapeutic delivery: Recent advances and future opportunities'. Together they form a unique fingerprint.
Cite this
Raut, S., Dasseux, J. L., Sabnis, N. A., Mooberry, L., & Lacko, A. (2018). Lipoproteins for therapeutic delivery: Recent advances and future opportunities. Therapeutic Delivery, 9(4), 257-268. https://doi.org/10.4155/tde-2017-0122